Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board

Recruiting now

Conditions studied: Incurable Disease

In brief

This study will evaluate the ability of a multidisciplinary group, the Evolutionary Tumor Board (ETB), to develop therapeutic strategies in patients without curative options.

Key facts

Study ID

NCT04343365

Run by

H. Lee Moffitt Cancer Center and Research Institute

People needed

35

Starts

2020-05-05

Expected to finish

2028-03-01

Last updated by the study team

2026-04-01

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be considered likely incurable given a standard of care. This is inclusive of participants in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but not curative options for care.
• Participant must have a life expectancy greater than 3 months
• Participant must have an ECOG performance status 0-2
• Participant and primary Oncologist are willing to consider the therapeutic strategies recommended by the ETB
• Willingness to be followed over time and allowing collection of clinical data including scans and serial blood sampling.

You may not qualify if…

• None

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.